Large-scale studies on the efficacy of P2Y12 antagonists to prevent thrombotic and inflammatory complications in SCD are lacking (3, 91), and further studies that include assessment of circulating levels of HMGB1 may assist in reconciling different outcomes found for P2Y12 inhibitors within prior studies. The gene discussed is HMGB1; the disease is Schnyder corneal dystrophy.